Results 121 to 130 of about 5,130,717 (259)

Anti‐Tubercular Drug‐Induced Liver Injury: Current Understanding and Emerging Directions

JGH Open, Volume 10, Issue 1, January 2026.
ABSTRACT Most common adverse effect causing cessation of anti‐tubercular treatment (ATT) is drug‐induced liver injury (DILI) which is unpredictable due to its idiosyncratic nature. ATT is the most common cause of DILI and drug‐induced acute liver failure (ALF) in South East Asia.
Shubham Prasad, Himanshu Narang, Saurabh Kedia, Vineet Ahuja   +3 more
wiley   +1 more source

Severe Hepatic Adverse Event Induced by Anti‐HER2 Therapy in Breast Cancer: A Case of Successful Immunotherapy With Baricitinib

ACR Open Rheumatology, Volume 8, Issue 2, February 2026.
Yufei Li, Yifan Wang, Miao Shao, Jing He
wiley   +1 more source

Effect of Butyrate‐Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab

JGH Open, Volume 10, Issue 1, January 2026.
ABSTRACT Aim The gut microbiome modulates immune responses, and butyrate‐producing bacteria have been linked to improved immune checkpoint inhibitor (ICI) efficacy. Conversely, proton pump inhibitors (PPIs) may negatively impact ICI outcomes by altering gut microbiota.
Kazuhiro Nouso, Akiko Wakuta, Shohei Shiota, Rio Fujita, Kazuya Kariyama, Atsushi Hiraoka, Masanori Atsukawa, Joji Tani, Toshifumi Tada, Shinichiro Nakamura, Kazuto Tajiri, Masaki Kaibori, Masashi Hirooka, Ei Itobayashi, Satoru Kakizaki, Atsushi Naganuma, Toru Ishikawa, Michitaka Imai, Tomoko Aoki, Hironori Tanaka, Takeshi Hatanaka, Kunihiko Tsuji, Kazuhito Kawata, Koichi Takaguchi, Akemi Tsutsui, Chikara Ogawa, Hironori Ochi, Yutaka Yata, Hidekatsu Kuroda, Tomomitsu Matono, Satoshi Yasuda, Hidenori Toyoda, Hiroko Iijima, Masatoshi Kudo, Takashi Kumada   +34 more
wiley   +1 more source

Holocarboxylase Synthetase Deficiency: A Second Case Report With Neonatal Cholestatic Liver Disease

JIMD Reports, Volume 67, Issue 1, January 2026.
ABSTRACT Holocarboxylase synthetase deficiency is an autosomal recessive inborn error of metabolism characterised by life‐threatening metabolic acidosis, ketoacidosis and hyperammonaemia through reduced biotin‐dependent carboxylase activity. We report the presentation of a Polynesian neonate with severe metabolic acidosis secondary to holocarboxylase ...
Sophie Manoy, Claire Murray, Matthew Lynch, Tahlee Minto, Kelvin Choo, Carolyn Bursle, Michelle Lipke, Jim McGill, Anita Inwood, David Coman   +9 more
wiley   +1 more source

Comparison of the effect of ursodeoxycholic acid and multistrain synbiotic on indirect hyperbilirubinemia among neonates treated with phototherapy: A double-blind, randomized, placebo-controlled clinical trial study

, 2023
Mitra Aldaghi, Elahe Babaie, Kazem Hassanpour, Mohammad Sahebkar   +3 more
openalex   +1 more source

Kinetics of hepatic bile acid handling in cholestatic liver disease: Effect of ursodeoxycholic acid

, 1994
Riadh P. Jazrawi, John de Caestecker, Patrick Goggin, A. J. Britten, Anton E. A. Joseph, J. D. Maxwell, T.C. Northfield   +6 more
openalex   +1 more source

Ursodeoxycholic acid therapy in hepatobiliary disease [PDF]

, 2000
Kris V. Kowdley
openalex   +1 more source

A retrospective integrated analysis evaluate the effect and safety of Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy [PDF]

, 2022
Guoyun Xuan, Ning liu, Dawei Ding, Ang Xu, Yinan Hu, Guanya Guo, Xi Chen, Yulong Shang, Ying Han   +8 more
openalex   +1 more source

Ursodeoxycholic acid in the treatment of liver diseases [PDF]

, 1997
Sushma Saksena, Radhika Tandon
openalex   +1 more source

Clinical Characteristics and Long‐Term Prognosis of Primary Biliary Cholangitis in Japan: Results of the 2nd‐Generation Nationwide Survey

Hepatology Research, Volume 56, Issue 1, Page 50-59, January 2026.
We have established the 2nd‐generation nationwide survey of PBC in Japan. Our analyses of the survey result not only highlight the demographical trend in Japanese PBC patients over time; they also validate the previously described risk factors for the patients' prognoses.
Yuki Kugiyama, Masanori Abe, Tadashi Namisaki, Hitoshi Yoshiji, Kazumichi Abe, Hiromasa Ohira, Ryosaku Shirahashi, Keiji Yokoyama, Atsushi Fukunaga, Kazuhito Kawata, Masahiro Umemura, Akira Honda, Tadashi Ikegami, Shiho Miyase, Toshiaki Nakano, Atsumasa Komori, Atsushi Tanaka, on behalf of the Japan PBC Study Group   +17 more
wiley   +1 more source